Meet the Mesothelioma Experts: Stephen Isaacs Discusses New Clinical Trial Using Listeria Bacteria

Stephen IsaacsOn September 10, the Meso Foundation will interview Stephen Isaacs, the chairperson, president, and CEO of Adura BioTech, during a new installment of the Foundation’s Meet the Mesothelioma Experts live broadcast. The interview will be led by the Meso Foundation’s executive director and mesothelioma expert nurse practitioner, Mary Hesdorffer, APRN.

The focus of the interview will be Audo BioTech’s experimental therapy for malignant pleural mesothelioma, known as CRS-207. CRS-207 is a weakened form of Listeria bacteria modified to reduce its ability to cause infections, but still able to stimulate the immune system.

The interview will be available live on September 10, at 1PM EST, by calling into a conference-call number. The interview is free of charge, but listeners must RSVP ahead of time by visiting curemeso.org/experts in order to receive a call-in number.

In his position at Aduro BioTech, Mr. Isaacs initiated the company’s current immunotherapy program based on attenuated strains of Listeria monocytogenes. He was responsible for recruiting key members of the current vaccine team with deep expertise in the biology of Listeria. Mr. Isaacs has published over 20 peer-reviewed scientific articles and is an inventor on over 40 issued patents.

To RSVP for the upcoming session with Stephen Isaacs or to listen to past Meet the Mesothelioma Experts sessions, visit curemeso.org/exerpts.

October Events: Regional Conference on Mesothelioma in Chicago

Chicago brochure coverThe 2014 Chicago Regional Conference on Malignant Mesothelioma is a one-day event geared to patients and family members, covering a variety of topics related to mesothelioma and presented by local and regional area experts. The conference is a collaborative effort between the Mesothelioma Applied Research Foundation and The University of Chicago Medicine.

The conference is geared towards patients (newly diagnosed or those looking to learn about second-line and beyond treatment options), caregivers, family members, general health practitioners, and anyone wishing to learn more about mesothelioma. Topics of discussion include imaging, genetics, surgery, chemotherapy, novel treatments, stem cells, immunotherapy, and resources for patients and families.

The location of the conference is the Palmer House Hilton at 17 E Monroe Street, Chicago, IL 60603. The event will begin at 9:30am and commence with a cocktail reception at 5pm. The registration cost is $25, and includes breakfast and lunch.

More information and registration is available at curemeso.org/chicago.

The Meso Foundation is also the host of an annual symposium, taking place in March of every year in the Washington, DC area, and another regional conference in Philadelphia in September.

September Events: Regional Conference on Mesothelioma in Philadelphia

The Meso Foundation and Penn’s Abramson Cancer Center will hold a mesothelioma conference on September 26.A mesothelioma conference presented by the Mesothelioma Applied Research Foundation and Penn’s Abramson Cancer Center, will be held in Philadelphia on September 26, 2014. The conference will bring together area experts in the field of mesothelioma. September 26 marks the National Mesothelioma Awareness Day.

The conference is open to the public, and specifically aimed at mesothelioma patients, family members, caregivers, healthcare professionals, and those who have been exposed to asbestos.

The conference will take place on Friday, September 26, 2014 at The HUB, Cira Centre at the Penn’s Abramson Cancer Center, located at 2929 Arch Street, Philadelphia, PA 19104. To register for the conference, visit OncoLink.org/Conference/Mesothelioma or call 800.789.PENN (7366) and press 2.

The conference is co-chaired by Mary Hesdorffer, CRNP, of the Meso Foundation, Joseph Friedberg, MD, of the Penn’s Abramson Cancer Center, and Daniel Sterman, MD, of the Penn’s Abramson Cancer Center. Among topics of discussion at the conference will be clinical trial participation, latest advances in peritoneal and pleural mesothelioma, palliative care, early detection, genetics, coping with mesothelioma, and survivorship.

Speakers include:
Mary Hesdorffer, CRNP, Mesothelioma Applied Research Foundation
Joseph Friedberg, MD, Penn’s Abramson Cancer Center
Chi Dang, MD, PhD, Penn’s Abramson Cancer Center
Julie Brahmer, MD, Johns Hopkins University
Richard Alexander, MD, University of Maryland
Lee Krug, MD, Memorial Sloan Kettering Cancer Center
Andreas Rimner, MD, Memorial Sloan Kettering Cancer Center
Daniel Sterman, MD, Penn’s Abramson Cancer Center
Suzanne Walker, CRNP, MSN, AOCN, BC, Penn’s Abramson Cancer Center
Anil Vachani, MD, Penn’s Abramson Cancer Center
Joseph Testa, PhD, Fox Chase Cancer Center
Eleanor Anderson, MD, Penn’s Abramson Cancer Center

For more information, visit curemeso.org.

Mark Your Calendar for Upcoming Mesothelioma Conferences

Two regional mesothelioma conferences are coming this fall to the University of Pennsylvania and the University of Chicago.This year, the Meso Foundation will be host to two regional conferences. The first will be held on Friday, September 26 at the University of Pennsylvania in Philadelphia, Pennsylvania. The second will be held on Friday, October 10 at the University of Chicago in Illinois. Each conference will feature regional experts in the field of mesothelioma. Check back to curemeso.org for further information as it becomes available or sign up for our e-news to ensure you are notified as conference details are released.

September 26, 2014
University of Pennsylvania
The Hub, Cira Centre
2929 Arch Street
Philadelphia, PA 19104

October 10, 2014
University of Chicago
Palmer House Hilton
17 E Monroe Street
Chicago, IL 60603

Annual Conference
The Meso Foundation’s annual conference, the International Symposium on Malignant Mesothelioma, along with the Scientific Seminar, will be held from Monday, March 2 through Wednesday, March 4, 2015 in partnership with the National Cancer Institute in Bethesda, Maryland. Events will be held at the National Institutes of Health Natcher Conference Center and the Hyatt Regency Bethesda. Symposium registration will open on October, 13, so mark your calendars now! Visit curemeso.org/symposium for more information as it becomes available or sign up for our e-news to be notified about Symposium details.

International Symposium
on Malignant Mesothelioma
March 2- 4, 2015
National Institutes of Health
Natcher Conference Center (Building 45)
Bethesda, MD
Hyatt Regency Bethesda
7400 Wisconsin Ave
Bethesda, MD 20814

Scientific Seminar
March 2-3, 2015
National Institutes of Health
Natcher Conference Center (Building 45)
Bethesda, MD

 

Summary of Mesothelioma Studies Presented at ASCO

Lee M. Krug, MD shares his annual summary of the mesothelioma research presented at the American Society of Clinical Oncology (ASCO) meeting.by Lee M. Krug, MD, Memorial Sloan Kettering Cancer Center

The American Society of Clinical Oncology meeting was held from May 30 – June 3, 2014 in Chicago. This is the largest oncology meeting each year with around 30,000 attendees from all over the globe who congregate to discuss the latest research in all cancer types. I will provide you with my annual summary of the most prominent studies in mesothelioma.

Randomized trial of arginine deprivation with ADI-PEG20: This abstract was presented by Dr. Szlosarek from the United Kingdom. Arginine is an amino acid that normal cells make using an enzyme called ASS (time to make the joke here!). However, many cancer cells lack the ASS enzyme so they cannot make arginine and they need to get it from outside the cell. ADI-PEG20 starves the cancer cells of arginine. In this trial, patients with mesothelioma were randomized to receive treatment with ADI-PEG20 or just supportive care. In order to qualify, the tumor samples were tested to make sure they had low levels of ASS. Side effects were very mild with this treatment. About half of the patients had stabilization of their disease. The time for cancer growth to occur was longer in the ADI-PEG20 arm, but only by a small margin (1.9 versus 3.2 months). A future study will combine ADI-PEG20 with chemotherapy, and that trial should open later this year.

Phase 2 study with tremelimumab: Probably the hottest drugs in oncology right now are the antibodies that boost the immune system. These types of treatment have shown great benefit in melanoma, lung cancer, and many others. Tremelimumab is one of these drugs, and this trial, conducted in Italy by Dr. Calabro and colleagues, showed that mesothelioma also responds to these therapies. Of the 29 patients, 14% of patients had shrinkage of their mesothelioma and 38% had stabilization. These data support the international, randomized trial with tremelimumab that is currently ongoing that will include 542 patients. If this large trial shows that tremelimumab improves survival, this drug will get FDA approval for mesothelioma.

Anti-mesothelin vaccine CRS-207 plus chemotherapy: Dr. Hassan from the National Cancer Institute reported these results. Mesothelin is a protein on the surface of mesothelioma tumors, and seems to be an excellent target for treatment. CRS-207 is a vaccine that increases the immune response against mesothelin. In this study, CRS-207 was given with pemetrexed and cisplatin. Nearly 70% of patients had shrinkage of their cancer, much more than usual with chemotherapy alone, and the responses seemed to last longer. These results should encourage a larger future randomized study.

Next-generation sequencing in mesothelioma: The report from Dr. Scagliotti at the University of Turin, Italy, described his findings from an analysis of gene mutations in a group of mesothelioma tumor samples. This type of testing has become critical for identifying potential targets in all cancers, and customizing treatment for each patient.


Lee M. Krug, MD, is an Associate Attending Physician in the Division of Thoracic Oncology, Department of Medicine at Memorial Sloan-Kettering Cancer Center in New York, New York, where he completed a fellowship and chief fellowship in medical oncology. Dr. Krug is the Director of the Mesothelioma Program at Memorial Sloan-Kettering Cancer Center. He is also the chair of the board of directors of the Meso Foundation.